Novo Nordisk struck a deal with Nanexa worth up to €1.165 billion (about $1.325 billion) for a global exclusive license to Nanexa’s long-acting drug delivery technology. The agreement is positioned to extend the duration of Novo’s peptides used in cardiometabolic pipelines. The technology deal directly intersects with Novo’s push toward longer-interval obesity injectables, aiming to improve dosing convenience and adherence while maintaining therapeutic exposure. For drug-delivery developers, the transaction highlights that incremental platform improvements—when paired with large franchise economics—can rapidly translate into major licensing value.